Aesthetic Medicine Market Size & Share 2026-2035

Aesthetic Medicine Market Size

The global aesthetic medicine market was valued at USD 23.2 billion in 2025 and is projected to increase from USD 25.6 billion in 2026 to USD 80.2 billion by 2035, at a CAGR of 13.5%. The market includes energy-based devices, injectables, implants, and skincare products and accessories used in surgical, minimally invasive, and non-surgical settings.

Procedure volumes provide the operating context for this expansion. ISAPS recorded nearly 38 million aesthetic procedures globally in 2024, including more than 17.4 million surgical and 20.5 million non-surgical procedures. Botulinum toxin was the most frequently performed non-surgical procedure, at approximately 7.8 million treatments, while hyaluronic acid procedures reached 6.3 million, up 5.2% from the preceding year ^[1]. The U.S. performed more than 6.1 million procedures, while Brazil recorded 3.1 million total procedures and led global surgical activity with 2.3 million procedures.

The market's growth is supported by a recurring-treatment base in injectables, a growing preference for procedures with limited recovery time, and device innovation that expands the range of treatable concerns. Demand is also becoming less dependent on conventional anti-aging use cases. Weight-loss pharmacotherapy is creating a clinically distinct cohort with facial volume loss, skin laxity, and body-contouring needs following rapid weight reduction ^[2], while medical spas are increasing access to routine injectable and energy-based treatments.

GLP-1-related weight loss adds demand, but it should not be treated as a uniform uplift across the market. Rapid weight reduction can create facial and body changes that require different treatment sequences, ranging from fillers and biostimulators to skin-tightening technologies and surgery. Providers that can assess tissue quality, weight-loss timing, and patient expectations across modalities are better positioned than clinics offering a single procedure category.

Europe presents the opposite side of the growth equation. Annex XVI regulation raises evidence and conformity requirements for specified aesthetic products without an intended medical purpose, increasing the burden on manufacturers and potentially favoring suppliers with regulatory resources and established clinical documentation. Growth therefore remains strong, but the share of that growth available to smaller device manufacturers may narrow as compliance deadlines approach.

Key Drivers

Increasing Awareness Regarding Aesthetic Procedures

Aesthetic procedures increasingly enter consumer consideration before a patient reaches a clinic. A systematic review covering 25 studies and 13,731 participants found that social-media exposure was associated with body dissatisfaction and greater consideration of cosmetic procedures among young adults ^[3]. Research from Boston University similarly identified a correlation between social-media use, including engagement with digital filters and influencers, and interest in cosmetic interventions.

This expansion of the awareness funnel has commercial consequences beyond patient acquisition. Providers can use digital channels to explain treatment sequencing, recovery expectations, and physician oversight, but the same channels can also compress consultation cycles and intensify price comparison. Demand growth is therefore strongest where awareness is paired with trusted clinical access and clear differentiation between supervised medical treatment and lower-quality alternatives.

Technological Advancements Associated with Medical Aesthetic Devices

Energy-based innovation broadens the range of concerns that can be addressed outside surgical settings. FDA clearances for radiofrequency systems, lasers, and light-based platforms demonstrate continuing product development across skin tightening, resurfacing, hair removal, and related indications ^[4]. The commercial value of these platforms lies less in the presence of a new wavelength or energy source alone than in whether providers can reliably incorporate it into a repeatable, profitable treatment protocol.

Clinical evidence also affects adoption. A prospective trial of high-intensity focused ultrasound reported improved elasticity in periorbital, perioral, and neck regions after treatment, without permanent adverse effects in the study population. A three-dimensional assessment reported statistically significant lifting effects across seven facial aesthetic units. Such evidence helps providers justify capital expenditure and can reduce patient hesitation where procedure outcomes are otherwise difficult to evaluate before purchase.

Rising Prevalence of Obesity

The underlying obesity burden is substantial. The World Health Organization reported that 890 million adults were living with obesity in 2022, representing 16% of adults globally. A pooled analysis of 3,663 population-representative studies found that obesity prevalence increased in 162 countries among women and 140 countries among men between 1990 and 2022.

For aesthetic medicine, obesity affects demand through body contouring, skin laxity management, and post-weight-loss procedures. A retrospective analysis of data across 30 U.S. states found a statistically significant association between GLP-1 receptor agonist use and higher rates of body-contouring surgery, including brachioplasty, panniculectomy, and breast procedures. The effect is not limited to surgical procedures: patients may also seek non-invasive modalities where residual laxity or contour concerns do not warrant surgery.

Increasing Adoption of Non-Invasive Procedures

Non-surgical procedures exceeded surgical procedures in the ISAPS 2024 survey, with 20.5 million non-surgical treatments compared with 17.4 million surgical procedures. Lower recovery burden, treatment reversibility in some injectable categories, and the ability to incorporate procedures into ordinary schedules reduce barriers for first-time and repeat patients.

The appeal of non-invasive care does not eliminate the need for clinical judgment. As procedure menus widen, providers must determine which concerns are appropriate for injectables, energy-based devices, or referral to surgical care. This favors practices that combine consultation capability with a broad modality mix rather than treating technology selection as a purely consumer-led decision.

Key Restraints

High Cost Associated with Aesthetic Procedures

Aesthetic medicine remains predominantly an out-of-pocket market. Surgical procedures require physician, facility, anesthesia, and follow-up costs, while many energy-based treatments require multiple sessions to achieve a clinically meaningful result. These economics constrain addressable demand in lower-income consumer segments and make procedure volumes more exposed to changes in disposable income and consumer confidence.

Cost also shapes provider behavior. Clinics may favor lower capital-intensity treatments, lease-based device arrangements, or platforms that serve multiple indications. In markets with less consistent enforcement or fragmented provider oversight, price pressure can steer patients toward lower-quality treatment settings, creating safety and reputational risks for the broader category.

Lack of Reimbursement and Stringent Regulatory Scenario

The elective character of most aesthetic procedures means reimbursement rarely offsets patient expenditure. This places device purchases and procedure demand on different economic cycles: patients may continue established injectable treatments while clinics postpone equipment acquisition during periods of high financing costs.

Regulation adds a separate constraint. Implementing Regulation (EU) 2023/1194 established transitional provisions for certain Annex XVI products. Products under Article 2(2) may be placed on the market until December 31, 2028, provided the required written Notified Body agreement is in place from January 1, 2027; products under Article 2(1), involving clinical investigations, have a December 31, 2029 deadline ^[5]. These provisions can slow launches and increase evidence-generation costs, but they also create a barrier against poorly documented products and increase the value of regulatory readiness.

Regenerative aesthetics illustrates a different constraint: demand may be strong, but treatment claims must remain aligned with the maturity of clinical evidence. A 2024 systematic review covering 13 studies identified applications of platelet-rich plasma in facial rejuvenation, hair restoration, and wound healing. Controlled studies have also evaluated PRP combined with fractional CO2 laser, fractional Er:YAG laser, and RF microneedling, indicating that combination protocols can be clinically investigated rather than marketed solely as additive treatments. The practical implication is that clinics need disciplined patient selection and standardized preparation protocols; a premium price is more defensible when the treatment pathway is evidence-led and reproducible.

Regulation and affordability place an upper boundary on expansion. Europe is likely to reward manufacturers that can absorb compliance costs and maintain market access through the Annex XVI transition. In lower-income markets, more accessible non-invasive treatments may grow faster in volume, but price-sensitive demand can limit provider margins and reduce the capacity for advanced equipment investment.

Aesthetic Medicine Market Segment Analysis

By Product

Injectables

Injectables generated approximately USD 11.1 billion in 2025 and are projected to reach USD 40.8 billion by 2035. Botulinum toxin is the leading injectable sub-segment, accounting for 29.78% of total market revenue and growing at a 13.5% CAGR. Its commercial position is reinforced by repeat-treatment intervals and a large base of trained injectors. ISAPS recorded about 7.8 million botulinum toxin procedures globally in 2024.

Dermal fillers accounted for 45.09% of total market revenue in 2025 and are forecast to grow at a 12.6% CAGR. Hyaluronic acid remains the dominant filler chemistry, supported by broad familiarity and reversibility characteristics. ISAPS recorded 6.3 million hyaluronic acid procedures globally in 2024. Longer-lasting non-HA products and collagen stimulators compete by changing the treatment interval and clinical objective, rather than simply substituting for standard HA fillers.

Implants represented 14.32% of the market in 2025. Breast implants accounted for 47.8% of implant revenue and are projected to grow at a 13.5% CAGR. ISAPS reported 3.9 million breast procedures globally in 2024. Surgical implants have a different demand profile from injectables: they involve higher patient commitment, longer decision cycles, and facility-dependent delivery, making them less suitable for the high-frequency treatment model that supports non-surgical care.

Energy-Based Devices

Energy-based devices represented 24.31% of market revenue in 2025. Laser-based systems lead the category with a 35.6% share and a 14.1% CAGR, followed by radiofrequency devices at 28.3%. The diversity of use cases, including resurfacing, hair removal, pigmentation treatment, vascular treatment, skin tightening, and body contouring, allows multi-application systems to improve utilization within clinics.

Innovation is shifting toward systems that make modality integration easier without overstating clinical equivalence between technologies. FDA clearance of Rohrer Aesthetics' PiXel8-RF in October 2023 provides an example of an FDA-cleared RF microneedling platform ^[7]. For buyers, the relevant question is not whether every modality can be housed in one unit; it is whether the system fits the practice's patient mix, treatment protocols, operator training requirements, and anticipated throughput.

By Gender

Female patients accounted for approximately 75.2% of global market revenue in 2025. This reflects the historical concentration of injectable and surgical procedure demand among women, while also leaving meaningful room for male participation to expand. ISAPS reported that women represented 85.5% of global aesthetic procedures in 2023.

Male patients represented 15.41% of market revenue in 2025 and are projected to grow at a 13.8% CAGR. Treatment demand is concentrated in facial injectables, skin tightening, hair restoration, and selected surgical procedures. The segment's growth rate reflects increased normalization, but providers need to avoid treating it as a homogeneous demographic; preferred outcomes, consultation dynamics, and repeat-treatment behavior can differ materially by procedure.

By Application

Facial aesthetics and anti-aging was the largest application segment, valued at USD 11.6 billion in 2025. It benefits from the widest product mix, including botulinum toxin, fillers, biostimulators, lasers, RF microneedling, and ultrasound. The category is also supported by repeat treatment cycles, making it central to practice revenue stability.

Body contouring and fat reduction is the fastest-growing application, with a 14.6% CAGR. Obesity prevalence and GLP-1-associated weight loss contribute to demand, but the clinical pathway ranges from localized non-invasive treatment to surgical intervention. The strongest providers will differentiate patients who are appropriate for device-based tightening or contouring from those requiring surgical referral.

Scar and pigmentation treatment is projected to grow at a 12.9% CAGR, while hair removal is forecast to grow at 12.2%. These applications can support predictable utilization of laser and light-based systems, but outcomes depend heavily on treatment parameters, skin type, and practitioner expertise. Skin resurfacing and rejuvenation is projected to grow at approximately 11.4%, supported by fractional laser and RF microneedling protocols.

By End Use

Hospitals generated USD 7.7 billion in 2025, representing 33.0% of market revenue. They remain the principal setting for complex surgical procedures requiring anesthesia, operating infrastructure, and post-procedure oversight. ISAPS reported that 52.6% of surgical procedures were performed in hospital settings globally.

Dermatology clinics accounted for 28.24% of market revenue in 2025. Their clinical positioning supports treatments requiring physician assessment and can sustain premium pricing where safety, skin-type expertise, or complication management are material considerations.

Beauty centers and medical spas held 26.01% of revenue in 2025 and are projected to grow at 13.4%, the fastest rate among end-use settings. Their expansion is linked to accessible non-surgical service formats and operational models built around recurring treatments. Ambulatory surgical centers, with a 10.79% market share, offer surgical capacity with lower overhead and more flexible scheduling than hospital-based programs.

Medical spas are strategically important because they can make routine aesthetic care more accessible and operationally standardized. Private equity activity demonstrates that multi-site expansion is becoming a tangible channel-development force in North America. Persistence Capital Partners closed more than C$375 million to support MedSpa Partners, which operated more than 40 clinics, in November 2023. Levine Leichtman Capital Partners invested in SEV, a medical-spa platform with 27 locations, in June 2023. Consolidation can improve procurement, marketing scale, and staff training, but it also raises the value of consistent clinical governance across sites.

GLP-1-related facial care reinforces the importance of product mix. Allergan Aesthetics reported that 47% of medical-weight-loss patients may benefit most from hyaluronic acid fillers. This does not imply that filler use substitutes for all post-weight-loss concerns; rather, it indicates that established injectable practices can capture part of the demand if they can evaluate tissue change accurately and integrate fillers with skin-quality, contouring, or surgical options when appropriate.

Aesthetic Medicine Market Regional Analysis

North America

North America was valued at USD 9,164.7 million in 2025, representing 39.5% of global revenue, and is projected to grow at approximately 13.4% CAGR. The U.S. generated USD 8.4 billion in 2025. Its market depth reflects high procedure awareness, practitioner availability, established injectable use, and a substantial medical-spa infrastructure.

The region is also at the forefront of GLP-1-related aesthetic demand. Allergan Aesthetics reported in March 2026 that 60% of surveyed GLP-1 users received their medications from aesthetic providers and that 52% of GLP-1 patients expressed concern about facial appearance. These findings suggest that aesthetic clinics and medical spa operators across North America are becoming an access point for medically supervised weight-loss patients as well as aesthetic aftercare. Providers must nonetheless distinguish evidence-based patient support from promotional claims that imply a uniform post-weight-loss treatment need.

Europe

Europe was valued at USD 6,838.4 million in 2025 and is projected to grow at approximately 13.7% CAGR. Germany, the UK, France, Spain, Italy, and the Netherlands are the principal covered markets. The region combines mature demand for injectables and energy-based care with increasingly stringent device regulation.

The Annex XVI transition is commercially consequential because it changes the cost and timing of European market access for affected products. Manufacturers with established clinical documentation and Notified Body planning may protect distribution continuity, while smaller suppliers may face a more difficult compliance path. Italy remains relevant both as a procedure market and as a manufacturing base for energy-based device suppliers, including El.En.

Asia Pacific

Asia Pacific was valued at USD 5,108.8 million in 2025 and is projected to grow at 14.5% CAGR, the fastest among regions. China, Japan, India, Australia, and South Korea form the core covered markets. Growth combines a large consumer base, increasing clinic density, strong consumer interest in non-surgical procedures, and expanding local device capabilities.

China has become a key commercial market for global suppliers. Bausch Health identified China and South Korea as major contributors to Solta Medical's 2024 growth, following NMPA approval of Thermage FLX and the TR-4 Return Pad in China in January 2024 ^[8]. South Korea's device industry is also extending its international presence. Industry participants and practitioners widely report that Chinese and South Korean manufacturers are increasing price competition in mid-tier energy-based devices, although the supplied evidence does not establish a standardized price differential. International suppliers therefore need to pair premium clinical positioning with local service, practitioner education, and regulatory execution.

Latin America

Latin America was valued at USD 1,375.6 million in 2025 and is projected to grow at 14.2% CAGR. Brazil is the region's anchor market, recording 3.1 million aesthetic procedures in 2024 and 2.3 million surgical procedures, the highest global surgical total. Mexico and Argentina provide additional growth potential, supported by urban demand and medical tourism.

The region's opportunity is constrained by affordability and currency volatility. Clinics and manufacturers must balance aspirational consumer demand with financing limitations and out-of-pocket payment capacity. Product portfolios that rely solely on premium imported platforms can face slower adoption outside leading metropolitan markets.

Middle East and Africa

Middle East and Africa generated USD 732.2 million in 2025 and is projected to grow at 13.7% CAGR. The UAE and Saudi Arabia are the principal revenue contributors, supported by higher income levels and concentration of premium healthcare infrastructure. Dubai and Abu Dhabi also draw patients from neighboring markets, while South Africa remains the principal sub-Saharan market.

Growth is uneven. GCC markets can support high-value surgical, injectable, and energy-based services, whereas fragmented infrastructure, differing regulatory requirements, and lower household purchasing power constrain broader regional penetration. Market participants must therefore prioritize selective city-level expansion rather than relying on regional averages.

North American consolidation creates an increasingly important buyer group for manufacturers. Multi-site medical-spa platforms can centralize purchasing and standardize treatment protocols, giving them more influence over device selection, training requirements, and consumables arrangements. Manufacturers that offer only equipment may be at a disadvantage relative to those able to support utilization, staff education, and commercial launch discipline.

In Asia Pacific, domestic manufacturing adds competitive pressure without eliminating the premium segment. Widely reported practitioner observations indicate that locally produced Chinese and South Korean platforms are increasing mid-tier competition. Global suppliers can preserve relevance where they demonstrate superior clinical evidence, service responsiveness, and practitioner confidence, but import-only strategies are likely to face more pressure as local regulatory and commercial capabilities deepen.

Europe's Annex XVI transition introduces a different form of market selection. The deadlines do not guarantee consolidation, but they create a material advantage for suppliers that complete conformity work early and maintain reliable access to Notified Body capacity. This makes regulatory planning a commercial capability, not merely a legal requirement.

Aesthetic Medicine Market Share & Competitive Landscape

The market is fragmented across injectables, implants, lasers, radiofrequency systems, light-based platforms, ultrasound technologies, and provider networks. Competitive advantage differs by category: injectables depend on brand trust, clinical education, and repeat usage; device suppliers depend on technology performance, service support, training, and utilization; implant manufacturers compete through safety evidence, product design, and surgeon relationships.

Sisram Medical Ltd

Sisram Medical operates across energy-based devices, injectables, and complementary aesthetic products, with Alma Lasers as the core device franchise. The company reported USD 349.1 million in revenue in 2024, while Asia Pacific revenue rose 6.0% to USD 116.2 million and Middle East and Africa revenue increased 27.1% to USD 34.6 million ^[9]. Its acquisition of PhotonMed International strengthened direct commercial infrastructure in China, and direct sales represented 87% of revenue in 2024, compared with 78% in 2023. This shift increases control over customer relationships but also raises exposure to local operating execution.

Boston Scientific Corporation

Boston Scientific is a diversified medical technology company, not an aesthetic medicine company. When it acquired Lumenis's surgical business in September 2021, Baring Private Equity Asia retained the Lumenis global aesthetics and ophthalmology businesses. Boston Scientific's MedSurg activities include endoscopy, urology, and neuromodulation, while its urology portfolio includes prosthetic urology and pelvic floor reconstruction. Its scale and procedural-medical expertise make it relevant to the wider MedTech environment, but it has no direct aesthetic medicine segment or aesthetic product line.

Merz Pharma / Merz Aesthetics

Merz Aesthetics markets Xeomin, Belotero, Radiesse, and Ultherapy. Merz reported EUR 1,024 million in revenue for FY2017/18, when Aesthetics and Specialty Neurology grew 19% on an ex-FX basis and represented 67% of healthcare revenue. Group revenue reached EUR 1,094 million in FY2018/19, up 6.8%. Ultherapy is the only FDA-cleared ultrasound device for non-surgical skin lifting, providing Merz with a differentiated device offering alongside its injectable portfolio.

Johnson & Johnson

Johnson & Johnson participates through its MedTech Surgery franchise and the Mentor breast implant portfolio. The Surgery franchise generated approximately USD 10.1 billion in 2024, reflecting the scale of J&J's broader surgical platform rather than aesthetic implant sales alone. Its position in breast aesthetics and reconstruction gives the company access to surgeon relationships and institutional channels that are less central to non-surgical aesthetic competitors.

Bausch Health Companies Inc.

Bausch Health participates through Solta Medical, which markets radiofrequency and energy-based systems, including Thermage FLX. Solta Medical generated USD 440 million in revenue in 2024, up 27% from USD 347 million in 2023, with reported constant-currency organic growth of 29%. China and South Korea contributed materially to the segment's growth, illustrating the importance of regulatory access and premium-device demand in Asia Pacific.

Cutera, Inc.

Cutera supplies aesthetic laser and energy-based platforms, including AviClear, Excel V+, truSculpt, and Secret Pro. It reported 2023 revenue of USD 212.4 million, down 16% from 2022, amid weaker capital-equipment demand. Its experience demonstrates the sensitivity of device specialists to clinic financing conditions, even where demand for procedures and consumables remains comparatively resilient.

Venus Concept

Venus Concept combines multi-technology aesthetic platforms with subscription and lease-based commercial arrangements. Its portfolio includes Venus Versa, Venus Legacy, Venus Viva, Venus Bliss, and ARTAS. Subscription arrangements represented approximately 26% of system revenue in 2024, while total revenue was USD 64.8 million, down from USD 76.4 million in 2023. The model lowers initial acquisition barriers for clinics, but the supplier must sustain utilization and collection performance over the duration of the customer relationship.

El.En. S.p.A.

El.En. is an Italian laser manufacturer supplying medical and aesthetic platforms under the DEKA brand. Its aesthetic segment generated approximately EUR 235.5 million in FY2024, up 4.2% year-on-year. FY2023 group revenue was EUR 692.3 million, with Medical & Aesthetic Systems accounting for about 57% of revenue. Its portfolio includes DEKA multi-application platforms, CO2 and erbium systems, and picosecond lasers, positioning the company across resurfacing and broader dermatological applications.

Huadong Medicine Co., Ltd. / Sinclair Pharma

Huadong Medicine owns Sinclair Pharma and has expanded its aesthetic portfolio through injectable and thread-lift products. Sinclair's portfolio includes MaiLi hyaluronic acid filler, Ellanse poly-caprolactone biostimulator, Silhouette InstaLift, and ATGC-110 botulinum toxin, for which Sinclair announced a global license in October 2023. Huadong reported aesthetic medicine segment revenue of approximately RMB 1.826 billion, or about USD 250 million, in FY2025; the portfolio was marketed in more than 55 countries. Revofil is not a Huadong or Sinclair brand.

Sciton, Inc.

Sciton develops laser and light systems around its JOULE platform. HALO TRIBRID uses three independently controlled wavelengths, 2940 nm, 1927 nm, and 1470 nm, on the JOULE X platform. Sciton reports that HALO treatments generate 59% higher revenue per session than competing laser categories. The strategic value of the modular platform is its ability to expand a practice's treatment menu while using a shared equipment architecture, although realized economics depend on patient mix and clinician utilization.

SharpLight Technologies Inc.

SharpLight was founded in 2004 and is headquartered in Israel, with distribution in more than 60 countries. Its Omnimax S4 combines DPC, RF, VermaDerm, and laser technologies across more than 60 indications. This multi-technology design is aimed at clinics seeking broad treatment capability from a consolidated device footprint.

Apax Partners

Apax Partners has influenced aesthetic medicine through targeted investments rather than direct product operations. Funds advised by Apax agreed to acquire Syneron Candela, subsequently renamed Candela, for approximately USD 397 million in April 2017. In January 2018, Apax Digital Fund led a USD 60 million Series D financing for SoYoung, an online aesthetic medical marketplace in China. These investments show how financial sponsors can shape both device ownership and patient-acquisition infrastructure.

GC Aesthetics plc

GC Aesthetics focuses on silicone gel breast implants under the Nagor, Eurosilicone, and CPG brands. The company cites more than 40 years of silicone gel implant history, availability in more than 70 countries, and more than 3 million implants placed globally. A 10-year Eurosilicone study involving 534 subjects, published in 2019, was described as the largest long-term European breast implant study at publication. The company also raised USD 20 million in Series D financing in 2016 and USD 97 million in 2018.

Vitruvian Partners LLP

Vitruvian Partners manages approximately EUR 16 billion in active funds and acquired Fotona Holdings (Netherlands) B.V. from AGIC Capital in October 2021. Fotona, established in Slovenia in 1964, produces medical laser systems for aesthetics, dentistry, and gynaecology. It sells directly in the U.S. and China and uses distributors in more than 65 countries. The investment highlights the appeal of globally distributed device businesses with established technical platforms and multiple specialty applications.

Hahn & Company

Hahn & Company is a South Korean private equity firm whose portfolio companies generate more than KRW 20 trillion in revenue. It launched a tender offer for Lutronic in June 2023 at an enterprise value of approximately KRW 957 billion, then acquired Cynosure in January 2024 and combined the businesses as Cynosure Lutronic in April 2024. The combined business operates direct sales in 12 countries and distributors in approximately 130 countries. Lutronic reported revenue of more than KRW 264 billion in 2022, with about 40% generated in the U.S..

Recent Industry Developments

Sisram Medical acquired PhotonMed International (June 2023)

Sisram completed the acquisition of PhotonMed International, strengthening its distribution and direct-market infrastructure in China.

EU Annex XVI transitional provisions entered into force (June 2023)

Implementing Regulation (EU) 2023/1194 set transitional conditions and deadlines for specified Annex XVI products, including the December 31, 2028 and December 31, 2029 market-placement deadlines for applicable categories.

Hahn & Company announced its Lutronic transaction (June 2023)

Hahn entered definitive agreements to acquire Lutronic in a transaction valued at approximately KRW 957 billion.

Rohrer Aesthetics' PiXel8-RF received FDA 510(k) clearance (October 2023)

The FDA cleared the RF microneedling platform on October 25, 2023.

Thermage FLX received NMPA approval in China (January 2024)

Approval of Thermage FLX and the TR-4 Return Pad supported Solta Medical's expansion in China.

Cynosure and Lutronic were combined as Cynosure Lutronic (April 2024)

Hahn & Company began the strategic merger of the two aesthetic-device businesses, creating a combined global platform with direct sales and distributor reach across multiple markets.

ISAPS published its Global Survey 2024 (June 2025)

The survey recorded nearly 38 million aesthetic procedures worldwide in 2024 and identified botulinum toxin and hyaluronic acid treatments as the leading non-surgical procedures.

Allergan Aesthetics released medical-weight-loss patient findings (March 2026)

The company reported that 60% of surveyed GLP-1 users received medications from aesthetic providers, while later data indicated that 52% of GLP-1 patients were concerned about facial appearance.